



Licensed products in pre-clinical & clinical phases

| Reference | Indication | R+D | Pre-clinical | Phase I | Phase II | Phase III | Licensed | Research group |
|--|---|-----|--------------|---------|----------|-----------|--|--|
| EYE-SCAFF project | LSCD syndrome | ▶ | | | | |  ferrer | CB06/01/0003 |
| Procedure for the procurement of solid micro- or nanoparticles | New types of administration of medicines | ▶ | | | | |  nanomol Technologies | CB06/01/0033 |
| Targeted delivery of therapeutic molecules to CXCR4 cells | Colorectal cancer | ▶ | | | | | NANOLIGENT | CB06/01/0014 CB06/01/1031 |
| Nanostructured proteins | Cancer | ▶ | | | | | NANOLIGENT | CB06/01/0014 CB06/01/1031 |
| Therapeutic nanoconjugates (1) | Cancer | ▶ | | | | | NANOLIGENT | CB06/01/0014 CB06/01/1031 |
| Functionalized liposomes for delivery of biactive compounds | Fabry disease | ▶ | | | | | Undisclosed | CB06/01/0033 CB06/01/0074 |
| Delivery of substances in senescent cells | Diseases where β -Gal is over-expressed | ▶ | | | | | senolytx | CB06/01/2012 |
| Therapeutic nanoconjugates (2) | Cancer | ▶ | | | | | NANOLIGENT | CB06/01/0014 CB06/01/1031 |